ROS

Mblue Labs Discovers Anti-Aging Power In Methylene Blue, Launches Bluelene Face&Neck Remodel Mask

Retrieved on: 
Wednesday, March 13, 2024
Scientific Reports, Health, Skin care, ECM, Face, Retinol, Radical (chemistry), Cell nucleus, Peptide, Extracellular matrix, DNA, Research, ROS, Mitochondrion, Methylene blue, Skin, Collagen, DNA repair, UMD, Identity matrix, Human, Ageing, Neck, Cosmetics

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.

Key Points: 
  • Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.
  • Mblue Labs, a woman and minority-owned business, is dedicated to advancing skincare science, and this latest product embodies their commitment to unparalleled innovation.
  • Methylene Blue penetrates skin cells at the mitochondrial level, creating cell health and proliferation.
  • To view an enhanced version of this graphic, please visit:
    The Face & Neck Remodel Mask features a powerful blend of the latest age-reversal ingredients, including Methylene Blue, Growth Factors, Advanced Peptides, and Niacinamide.

Wind River Showcases New Levels of Machine Intelligence with AI-Driven Edge Applications at NVIDIA GTC

Retrieved on: 
Tuesday, March 19, 2024
Electronic Design Automation, Security, Data Management, Technology, Audio, Video, Apps, Applications, 5G, Artificial Intelligence, General Automotive, Telecommunications, Automotive, Software, Networks, Internet, Mobile, Wireless, Nvidia Jetson, Element, Wind, GTC, Algorithm, FPS, Environment, CUDA, Pedestrian, Metric prefix, ROS, AI, Linux, Yaskawa Electric Corporation, Life, Deep learning, Robotics, Yocto Project, Safety, Machine learning, San Jose Convention Center, NVIDIA, Human, Medical device

In the demonstration, the combination of the Yocto Project–based Wind River Linux and NVIDIA Jetson Orin™ provides a groundbreaking, CUDA -optimized solution for real-time object recognition in dashcam videos.

Key Points: 
  • In the demonstration, the combination of the Yocto Project–based Wind River Linux and NVIDIA Jetson Orin™ provides a groundbreaking, CUDA -optimized solution for real-time object recognition in dashcam videos.
  • When NVIDIA technology is combined with Yocto Project open source Linux, next-generation AI is enabled,” said Paul Miller, chief technology officer, Wind River.
  • Wind River Linux offers high stability and security to meet the high-performance needs of mission-critical applications.
  • To view Wind River technologies firsthand at NVIDIA GTC , taking place March 18–21, visit Wind River at booth #140.

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diagnosis, Pharmacology, LD, Conference, Survival, Serum, Coya, Disease, ALS, Associate, Patient, Biomarker, COYA, ROS, Death, Reactive oxygen species, Society, Therapy, Patent, FDA, Oxidative stress

The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.
  • In a proof-of-concept study in patients with ALS, the combination of low dose interleukin-2 (LD IL-2) and CTLA-4 Ig appeared to lower 4-HNE and other proinflammatory biomarker levels.
  • Furthermore, Coya has filed patent applications relating to the use of the biomarker in ALS.
  • Data was collected from a previously established biobank at Houston Methodist to monitor and track ALS patient outcomes with biomarkers.

Global and China Software-defined Vehicle Industry Research, Panorama and Strategy Report 2023-2024: How to Build Intelligent Driving Software-defined Vehicle (SDV) Architecture?

Retrieved on: 
Friday, March 15, 2024
Cloud, OS, Intel, NIO, SOC, OTA, TBOX, Vehicle, Li Auto, Drive, RT, DDS, Perception, Data collection, ROS, Build automation, FCW, SDV, QNX, RTLinux, Intelligence, Architecture, EEA, Engineering, Huawei, FSD, OpenHarmony, HD, HMI, ALC, Map, Android, LDW, Human, Video game

Autonomous driving R&D links mainly involve software engineering and hardware engineering:

Key Points: 
  • Autonomous driving R&D links mainly involve software engineering and hardware engineering:
    Basic software for intelligent driving: real-time vehicle control operating system (narrowly defined OS), intelligent driving middleware (ROS, CyberRT, DDS, AutoSAR), autonomous driving operating system (broadly defined OS), etc.
  • );
    General algorithm training for intelligent driving: AI deep learning software platform, intelligent driving data training set, etc.
  • Intelligent driving hardware system design: computing platform hardware system architecture design, vehicle chip system design, vehicle sensor system design, etc.
  • 1.5 Construction of Universal Algorithms for Intelligent Driving: from Small Models to Large Models
    1.6 Intelligent Driving General Algorithm Architecture: AI Deep Learning Software Platform
    1.9 Intelligent Driving Terminal-cloud Integration: Data Closed-loop
    1.10 Intelligent Driving Terminal-Cloud Integration: Data Collection & Annotation
    1.11 Intelligent Driving Terminal-Cloud Integration: Simulation Testing: Scenario Library
    1.12 Intelligent Driving Terminal-Cloud Integration: Simulation Testing: Simulation Platform
    1.13 Intelligent Driving Terminal-Cloud Integration: Cloud Native and Storage Platform
    1.14 Intelligent Driving Terminal-Cloud Integration: HD Map
    1.15 Intelligent Driving Assistance Software: ADAS Performance Evaluation
    1.16 Intelligent Driving Assistance Software: ADAS Data Recording
    2 How to Build Intelligent Cockpit Software System?

Roscan Gold Announces Debt Settlement and Proposed Financing

Retrieved on: 
Wednesday, February 21, 2024
TSX Venture Exchange, Person, USD, Finance Secretary (India), Note, Gold, CAD, Indian stock exchange, Legislation, Debt settlement, ROS, Offering, Security (finance)

Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Roscan Gold Corporation (TSXV: ROS) (FSE: 2OJ) (OTCQB: RCGCF) ("Roscan" or the "Company") is pleased to announce that it has agreed to settle (the "Debt Settlement") an aggregate of USD$1,005,000 debt owed to an arm's length creditor through the issuance of a secured convertible promissory note (the "Note").

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Roscan Gold Corporation (TSXV: ROS) (FSE: 2OJ) (OTCQB: RCGCF) ("Roscan" or the "Company") is pleased to announce that it has agreed to settle (the "Debt Settlement") an aggregate of USD$1,005,000 debt owed to an arm's length creditor through the issuance of a secured convertible promissory note (the "Note").
  • The Note issued pursuant to the Debt Settlement shall be secured by way of a general security agreement providing security ranking subordinate to the other secured indebtedness of the Company, over all of the present and after-acquired property of the Company.
  • It is expected that insiders of the Company will participate in the Offering for CAD$400,000 principal amount of Convertible Notes.
  • All securities issued in connection with the Offering and the Debt Settlement will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Retrieved on: 
Friday, March 8, 2024
Assay, Cancer, JNK, NLRP3, AACR, IIS, Biochemistry, Cellular, Therapy, Reactive oxygen species, Tumor microenvironment, Patient, ROS, Research, Pharmaceutical industry

“The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.

Key Points: 
  • “The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.
  • We are pleased to present new preclinical studies that explore the molecular targets for rigosertib, in clinical development through a series of investigator initiated studies (IIS),” commented Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • “The studies provide additional prospective on the main cellular pathways impacted by rigosertib, including RAS-MAPK signaling and reactive oxygen species (ROS)-related proteins.
  • Conclusions: This work identified a series of cellular and inflammatory targets that may be affected by rigosertib.

Cogniteam Selects RTI Connext® to Enable Seamless Communication within its Cloud Robotics Platform

Retrieved on: 
Tuesday, March 5, 2024
Atmosphere, DDS, Library, Data Distribution Service, Communication, Matrix, Ecosystem, RTI, RMW, ROS, Robotics

Cogniteam brings users a unique robotic AI solution in one place to design, develop and test robots.

Key Points: 
  • Cogniteam brings users a unique robotic AI solution in one place to design, develop and test robots.
  • By leveraging Connext, based on the Data Distribution Service (DDS™) standard, developers can monitor incoming data in real-time from robots to the cloud.
  • “Robotics are enabling efficient autonomy and productivity in nearly every vertical,” said Bob Leigh, Senior Director of Commercial Markets at RTI.
  • To learn more about RTI Connext, please visit the RTI website .

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, March 4, 2024
IOV, NSCLC, SAN, EGFR, TIL, FDA, Food, Lung cancer, Safety, Patient, ROS, ALK, Cancer, Pharmaceutical industry

In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring.

Key Points: 
  • In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring.
  • Upon reviewing this proposal, the FDA has cleared Iovance to resume patient enrollment in IOV-LUN-202.
  • Iovance expects to complete enrollment of approximately 120 patients in the IOV-LUN-202 registrational cohorts in 2025.
  • Preliminary data from the IOV-LUN-202 trial support the potential benefit of one-time TIL therapy, including the opportunity for more durable responses than available second line chemotherapies.

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Reactive oxygen species, Alzheimer's disease, MicroRNA, Inflammation, OTC, LPS, Schizophrenia, Nitric oxide, Cell, Factorization of polynomials, Safety, Protein, Clinical trial, Gene, DSM-IV codes, ROS, Hebrew University of Jerusalem, Microglia, Anoxic waters, Spectrum, Al-Quds, Research, Cannabidiol, Pharmaceutical industry

Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.

Key Points: 
  • Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.
  • The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model.
  • “We are excited to finally receive the positive results from our preclinical study, which was our first step in validating our novel, cannabinoid based therapeutic,” said Aitan Zacharin, GCANRx CEO.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

Study Illustrates Zeropollution's Enhancing Skin's Resilience to Environmental Damage

Retrieved on: 
Tuesday, March 5, 2024
Quercetin, Lippia, Air pollution, Woman, Capsule, Elasticity, Doctor of Philosophy, Oleuropein, Rosmarinus, Aryl hydrocarbon receptor, Inflammation, Free-radical theory of aging, Pollution, HPLC, Heart rate, Skin, Volunteering, Molecular biology, Radiation, Health, Lipid peroxidation, Caturla, Hesham Tillawi, Sophora, Drink, Reactive oxygen species, Journal, Clinical trial, Oxidative stress, ROS, Endothelium, Tissue, Núria, Antioxidant, DNA, Beauty, Dietary supplement

MADRID, March 5, 2024 /PRNewswire/ -- A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level.

Key Points: 
  • This patented multi-herbal cosmeceutical has been crafted to synergistically strengthen the skin's protective barrier against environmental insults through an "inside out" approach.
  • The study led by Laurent Peno-Mazzarino was published in the Journal of Current Issues in Molecular Biology in January 2024.
  • This encompasses reactive molecules generated by factors such as UV radiation, pollution, and other environmental stressors that can damage cells and tissues.
  • In this study, Zeropollution successfully counteracted the adverse effects of urban dust on the heart rate of zebra fish embryos.